Brought to you by 
Xcyte raises $29.9mm in IPO
17 Mar 2004
Executive Summary
Xcyte Therapies (immune response enhancing drugs) netted $29.9mm in its initial public offering through the sale of 4.2mm shares priced at $8 per share. The company previously filed for an $86mm initial offering in December of 2000, but later withdrew it due to market conditions; the current IPO was preliminarily priced between $13-15 apiece for 4mm shares.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Xcyte raises $29.9mm in IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice